CI-581a

Phase 3Small molecule

NNew York State Psychiatric Institute

CI-581a is one of 23 small molecule programs targeting Cocaine Use Disorder. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cocaine Use DisorderActive, not recruiting

Cocaine Use DisorderPhase 3

Active, not recruiting

Competition

Competitive Landscape

26 competitors in Cocaine Use Disorder

#DrugCompanyPhaseTrials

Rocaltrol

Alnylam Pharmaceuticals

Actos

Cortef

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

1 4

Pitocin

Ozempic

2 6

Vraylar

AbbVie

Phase 2

1 7

Revia

Teva

Phase 2

1 8

Suboxone

IIndivior Inc.

Phase 2

1 9

Lorcaserin

Eisai

Phase 2

3 10

Byetta

AstraZeneca

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Alcohol Use1 trial

Glutamatergic Modulation of Disordered Alcohol Use

Completed·NNew York State Psychiatric Institute·Phase 2/3·NCT02539511·50 enrolled

AIN1 trial

The Effect of Glutamatergic Modulation on Cocaine Self-administration

Completed·NNew York State Psychiatric Institute·Phase 2·NCT02596022·18 enrolled

ESS1 trial

The Role of Brief Potent Glutamatergic Modulation in Addressing Problem Drinking

Unknown status·NNew York State Psychiatric Institute·Phase 2·NCT04084860·120 enrolled

Cannabis Use Disorder1 trial

Facilitating the Behavioral Treatment of Cannabis Use Disorder

Completed·NNew York State Psychiatric Institute·Phase 1·NCT02946489·8 enrolled

Cocaine Use Disorder1 trial

Glutamatergic Modulation to Facilitate the Behavioral Treatment of Cocaine Use Disorders

Suspended·NNew York State Psychiatric Institute·Phase 3·NCT03344419·150 enrolled

1 more indication

Depressive Symptoms1 trial

Glutamatergic Modulation as a Treatment for Depressive Symptoms Among Patients With Post-acute Sequelae of COVID (PASC): A Pilot Trial

Active, not recruiting·NNew York State Psychiatric Institute·Phase 2·NCT05690503·12 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for CI-581a. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CI-581a compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CI-581a. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — New York State Psychiatric Institute company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: NNew York State Psychiatric Institute

CI-581a

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Alcohol Use1 trial

AIN1 trial

ESS1 trial

Cannabis Use Disorder1 trial

Cocaine Use Disorder1 trial

Depressive Symptoms1 trial

References

Drug Info

Quick Facts

Related News